263 related articles for article (PubMed ID: 30860937)
21. Impact of oncology pharmacist-managed oral anticancer therapy in patients with chronic myelogenous leukemia.
Lam MS; Cheung N
J Oncol Pharm Pract; 2016 Dec; 22(6):741-748. PubMed ID: 26419691
[TBL] [Abstract][Full Text] [Related]
22. The Expanding Role of the Oncology Pharmacist.
Holle LM; Segal EM; Jeffers KD
Pharmacy (Basel); 2020 Jul; 8(3):. PubMed ID: 32722357
[TBL] [Abstract][Full Text] [Related]
23. Perceptions of pharmacists' role in the health care team through student-pharmacist led point-of-care screenings and its future application in health care.
Bastianelli KMS; Nelson L; Palombi L
Curr Pharm Teach Learn; 2017; 9(2):195-200. PubMed ID: 29233403
[TBL] [Abstract][Full Text] [Related]
24. Assessment of the Role of the Pediatric Nurse in Patient Education and Follow-up of Patients Receiving Oral Anticancer Treatment.
Shinnick S
J Pediatr Oncol Nurs; 2020; 37(1):46-54. PubMed ID: 31475636
[No Abstract] [Full Text] [Related]
25. Current challenges in European oncology pharmacy practice.
Hoppe-Tichy T
J Oncol Pharm Pract; 2010 Mar; 16(1):9-18. PubMed ID: 20015932
[TBL] [Abstract][Full Text] [Related]
26. Pharmaceutical counseling: Between evidence-based medicine and profits.
Egorova SN; Akhmetova T
Int J Risk Saf Med; 2015; 27 Suppl 1():S87-8. PubMed ID: 26639727
[TBL] [Abstract][Full Text] [Related]
27. Dose Rounding of Biologic and Cytotoxic Anticancer Agents: A Position Statement of the Hematology/Oncology Pharmacy Association.
Fahrenbruch R; Kintzel P; Bott AM; Gilmore S; Markham R
J Oncol Pract; 2018 Mar; 14(3):e130-e136. PubMed ID: 29400987
[TBL] [Abstract][Full Text] [Related]
28. Impact of a formal pharmacist-run oral antineoplastic monitoring program: A pilot study in an adult genitourinary oncology clinic.
Conliffe B; Figg L; Moffett P; Lauterwasser L; Parsons LB
J Oncol Pharm Pract; 2019 Jun; 25(4):777-786. PubMed ID: 29375014
[TBL] [Abstract][Full Text] [Related]
29. Pharmacy Emergency Preparedness and Response (PEPR): a proposed framework for expanding pharmacy professionals' roles and contributions to emergency preparedness and response during the COVID-19 pandemic and beyond.
Aruru M; Truong HA; Clark S
Res Social Adm Pharm; 2021 Jan; 17(1):1967-1977. PubMed ID: 32389631
[TBL] [Abstract][Full Text] [Related]
30. Utilization patterns for oral oncology medications in a specialty pharmacy cycle management program.
Deutsch S; Koerner P; Miller RT; Craft Z; Fancher K
J Oncol Pharm Pract; 2016 Feb; 22(1):68-75. PubMed ID: 25301744
[TBL] [Abstract][Full Text] [Related]
31. Novel mobile application for direct communication between pharmacists and patients treated with oral antineoplastic agents.
Collado-Borrell R; Escudero-Vilaplana V; Ribed A; Jiménez RR; Peinado II; Herranz-Alonso A; Sanjurjo-Sáez M
Am J Health Syst Pharm; 2020 Aug; 77(17):1393-1402. PubMed ID: 32620958
[TBL] [Abstract][Full Text] [Related]
32. Challenges of Caregivers of Cancer Patients who are on Oral Oncolytic Therapy.
Marshall VK; Cairns PL
Semin Oncol Nurs; 2019 Aug; 35(4):363-369. PubMed ID: 31229341
[TBL] [Abstract][Full Text] [Related]
33. Impact of clinical pharmacy in oncology and hematology centers: A systematic review.
Oliveira CS; Silva MP; Miranda ÍKSPB; Calumby RT; de Araújo-Calumby RF
J Oncol Pharm Pract; 2021 Apr; 27(3):679-692. PubMed ID: 33302824
[TBL] [Abstract][Full Text] [Related]
34. Enhancing pharmacists' role as oral health advisors.
Cohen LA
J Am Pharm Assoc (2003); 2013; 53(3):316-21. PubMed ID: 23699681
[TBL] [Abstract][Full Text] [Related]
35. Expansion of pharmacist practice in oral oncolytic therapy with a collaborative practice agreement.
Wright AL; Matta SF; Kerr JR
J Oncol Pharm Pract; 2020 Dec; 26(8):1886-1893. PubMed ID: 32075505
[TBL] [Abstract][Full Text] [Related]
36. Evaluating the patient-perceived impact of clinical pharmacy services and proactive follow-up care in an ambulatory chemotherapy unit.
Crespo A; Tyszka M
J Oncol Pharm Pract; 2017 Jun; 23(4):243-248. PubMed ID: 26911478
[TBL] [Abstract][Full Text] [Related]
37. Are community pharmacists equipped to ensure the safe use of oral anticancer therapy in the community setting? Results of a cross-country survey of community pharmacists in Canada.
Abbott R; Edwards S; Whelan M; Edwards J; Dranitsaris G
J Oncol Pharm Pract; 2014 Feb; 20(1):29-39. PubMed ID: 24103897
[TBL] [Abstract][Full Text] [Related]
38. Evaluation of Chemotherapy Regimen Management Practice by Oncology-Specialized and Non-specialized Pharmacists Collaboration.
Saito Y; Uchiyama K; Sakamoto T; Kubota K; Oki H; Iwai M; Takekuma Y; Komatsu Y; Sugawara M
Biol Pharm Bull; 2021; 44(3):293-297. PubMed ID: 33642541
[TBL] [Abstract][Full Text] [Related]
39. Development and implementation of an interdisciplinary oncology program in a community hospital.
Chung C; Collins A; Cui N
Am J Health Syst Pharm; 2011 Sep; 68(18):1740-7. PubMed ID: 21880891
[TBL] [Abstract][Full Text] [Related]
40. Improved Adherence Rates and Clinical Outcomes of an Integrated, Closed-Loop, Pharmacist-Led Oral Chemotherapy Management Program.
Muluneh B; Schneider M; Faso A; Amerine L; Daniels R; Crisp B; Valgus J; Savage S
J Oncol Pract; 2018 Jun; 14(6):e324-e334. PubMed ID: 29799768
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
